Skip to main content
Dot gov

Official websites use the Texas HHS logo.
The Texas HHS logo means this is an official website of Texas Health and Human Services.

HTTPS

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

4. References

  1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2021. Available at: http://www.clinicalpharmacology-ip.com.ezproxy.lib.utexas.edu/. Accessed December 8, 2023.
  2. Ivacaftor (Kalydeco) package insert. Vertex Pharmaceuticals, Inc., August 2023.
  3. Lumacaftor/ivacaftor (Orkambi) package insert. Vertex Pharmaceuticals, Inc., August 2023.
  4. Tezacaftor/ivacaftor tablets; ivacaftor tablets (Symdeko) package insert. Vertex Pharmaceuticals, Inc., August 2023.
  5. Elexacaftor/tezacaftor/ivacaftor tablets; ivacaftor tablets (Trikafta) package insert. Vertex Pharmaceuticals, Inc., August 2023.
  6. Wright CC, Vera YY. Chapter 46. Cystic fibrosis. In: DiPiro JT, Yee GC, Posey LM, et al, eds. Pharmacotherapy: a pathophysiologic approach. 11th ed. New York: McGraw-Hill; 2019. Available at:  https://accesspharmacy-mhmedical-com.ezproxy.lib.utexas.edu/content.aspx?bookid=2577&sectionid=219316881. Accessed December 8, 2023.
  7. Simon RH. Cystic fibrosis: treatment with CFTR modulators. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com (Accessed on December 8, 2023.)
  8. Konstan MW, McKone EF, Moss RB, et al. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet Respir Med. 2017;5(2):107-18.
  9. Heltshe SL, Rowe SM, Skalland M, et al. for the GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Ivacaftor-treated patients with cystic fibrosis derive long-term benefit despite no short-term clinical improvement. Am J Respir Crit Care Med. 2018;197(11):1483-6.